Lawsuits mount in wake of rofecoxib (Vioxx) withdrawal

Kondro, Wayne
November 2004
CMAJ: Canadian Medical Association Journal;11/23/2004, Vol. 171 Issue 11, p1335
Academic Journal
Reports on the legal fallout of the decision of Merck & Co. to withdraw the anti-arthritis drug rofecoxib (Vioxx) in the market. Reasons for the drug's withdrawal; Class-action lawsuits filed by lawyers against the firm and its Canadian subsidiary, Merck Frosst Canada; Statement of Merck Frosst Canada on the lawsuits; Criticism on the failure of Merck to undertake adequate safety testing on rofecoxib.


Related Articles

  • Court hears how Merck tried to "neutralise" critics of Vioxx. Moynihan, Ray // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;4/11/2009, Vol. 338 Issue 7699, p849 

    The article discusses an alleged plan by Merck, the manufacturer of Viox, to discredit influential physicians and researchers who criticized the use of the drug. The e-mails discussing the plan and a list of physicians was revealed during an Australian class action suit. The civil action...

  • Merck's Pain Sharpens. Quinn, William T. // njbiz;10/11/2004, Vol. 17 Issue 41, p6 

    Discusses issues concerning the individual lawsuits and at least one class action filed on behalf of Vioxx painkiller users against New Jersey-based pharmaceutical company Merck. Side effects of the long-term use of Vioxx on health; Expected final cost to cover the complaints of users; Annual...

  • Quebec allows Vioxx class-action suit. Sibbald, Barbara // CMAJ: Canadian Medical Association Journal Supplement;1/2/2007, Vol. 176 Issue 1, p20 

    The article reports on the decision of the Quebec Superior Court to grant plaintiffs class-action status in a suit against pharmaceutical company Merck Frosst Canada Ltd. The Court has authorized the class action filed by plaintiffs who allegedly suffer from heart attack after using rofecoxib....

  • Heart Attack.  // Business News New Jersey;May/Jun2001, Vol. 14 Issue 22, p3 

    Focuses on the response of Merck on the association of arthritis drugs Vioxx and Celebrex with the risk of heart disease in the United States. Comparison between the probability of risks caused by the drugs and older pain killers; Utilization of naproxen for heart attack prevention; Impact of...

  • The problem with new drugs. Weinstein, Bill // Henley Manager Update;Winter2006/2007, Vol. 18 Issue 2, p1 

    The article focuses on the withdrawal by U.S.-based pharmaceutical company Merck of Vioxx, a new type of drug which had given pain relief to those suffering from arthritis and other causes of pain, on September 30, 2004. This drug was one of the company's most profitable products with annual...

  • Plaintiffs Want Peek at Sealed Records. Reisinger, Sue // Corporate Legal Times;Feb2003, Vol. 13 Issue 135, p54 

    Reports that New Jersey-based Merck & Co. Inc. has offered in December 2002 to pay $42.5 million to settle five years of class-action lawsuits accusing its Medco Health Solutions unit of overcharging customers.

  • Vioxx Controversy. Stephenson, Joan // JAMA: Journal of the American Medical Association;12/15/2004, Vol. 292 Issue 23, p2827 

    Reports that a team of researchers from Great Britain and Switzerland have found that the arthritis drug Vioxx should have been pulled from the market four years ago. Questioning of the drug's safety since 2000 when a trial showed a 5-fold higher incidence of myocardial infarction in patients on...

  • Dizziness in a cardiac rehabilitation patient. Cantwell, John D.; Shrake, Linda // Physician & Sportsmedicine;Feb97, Vol. 25 Issue 2, p89 

    Examines the electrocardiographic (ECG) reading of a 62-year-old female under cardiac rehabilitation for episodic atrial fibrillation. Medications taken for atrial fibrillation; Blood chemistry test results; Torsades de pointes as ECG diagnosis; Proarrhythmic risks carried by many...

  • Merck to face consolidated class actions in federal court. Parekh, Rupal // Business Insurance;2/21/2005, Vol. 39 Issue 8, p17 

    This article reports that Merck & Co. Inc. is one step closer to facing former Vioxx users in court, after a ruling last week consolidated hundreds of individual and class action lawsuits brought against the drug company by plaintiffs alleging the painkiller caused heart damage, kidney failure...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics